Probiotics Enhance GLP-1/GLP-2 Secretion, Improving Glycemic Control in Type 2 Diabetes
Background
The global prevalence of Type 2 Diabetes (T2D) continues to rise, driven by factors including lifestyle and gut microbiota dysbiosis. A key aspect of T2D pathophysiology involves impaired incretin responses, particularly reduced Glucagon-Like Peptide-1 (GLP-1) secretion, which is crucial for glucose-dependent insulin release and glycemic control. Current T2D treatments often target the incretin system, but there's a growing interest in leveraging the gut microbiota to naturally enhance incretin production. Understanding how probiotics can modulate the gut-derived incretin axis, including GLP-1 and GLP-2, offers a promising avenue for novel therapeutic strategies to address this critical metabolic imbalance.
Study Design
This narrative review synthesized literature from PubMed, Scopus, and Google Scholar to examine the role of probiotics in modulating the gut-derived incretin peptide axis in Type 2 Diabetes. Researchers prioritized recent literature from 2015 to 2025, including randomized controlled trials, meta-analyses, systematic reviews, and relevant preclinical studies. Earlier landmark studies were included only when they established foundational mechanisms related to incretin biology, SCFA-FFAR signaling, or GLP-1 secretion physiology. The review focused on both conventional and engineered probiotic approaches, emphasizing GLP-1, GLP-2, and microbial metabolite signaling.
Results
The review found that probiotics promote GLP-1 secretion primarily through the action of Short-Chain Fatty Acids (SCFAs) binding to FFAR2/3 receptors on enteroendocrine cells. This mechanism leads to improved glycemic control, as evidenced by multiple meta-analyses, although with noted heterogeneity across studies. Conventional probiotics demonstrated benefits in modulating the incretin axis and improving metabolic parameters. However, the review highlighted that engineered probiotic systems, such as LgsGPA, showed superior preclinical efficacy. These advanced systems were observed to alleviate hyperglycemia more effectively and restore β-cell function in experimental models. The findings underscore the potential of microbial interventions to positively influence the gut-derived incretin peptide axis in Type 2 Diabetes.
Engineered probiotics like LgsGPA demonstrated superior preclinical efficacy in alleviating hyperglycemia and restoring β-cell function compared to conventional probiotics.
Key Findings
- Probiotics promote
GLP-1secretion via Short-Chain Fatty Acids (SCFAs) binding toFFAR2/3receptors. - Conventional probiotics improve glycemic control in Type 2 Diabetes, as supported by meta-analyses.
- Engineered probiotics, such as LgsGPA, show superior preclinical efficacy in reducing hyperglycemia.
- Engineered probiotics demonstrate potential for restoring
β-cellfunction in preclinical models. - Significant heterogeneity exists in the glycemic outcomes observed with conventional probiotic interventions.
Why It Matters
This review consolidates compelling evidence that probiotics, both conventional and engineered, can significantly modulate the gut-derived incretin axis, offering a novel approach to Type 2 Diabetes management. For individuals with T2D, incorporating specific probiotic strains could become a valuable adjunct to existing therapies, potentially improving glycemic control and reducing reliance on pharmacological interventions. The emergence of engineered probiotics like LgsGPA signals a future where highly targeted, personalized microbial therapies could offer superior efficacy in restoring pancreatic β-cell function and alleviating hyperglycemia. While conventional probiotics offer accessible benefits, the path for engineered systems requires substantial clinical validation and regulatory development before becoming a usable protocol, but it opens exciting possibilities for precision medicine in metabolic health.
probiotics
glp-1
glp-2
type-2-diabetes
gut-microbiota
incretin